Advertisement
Advertisement
U.S. markets open in 1 hour 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gracell Biotechnologies Inc. (GRCL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5100+0.0500 (+1.45%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.4600
Open3.5300
Bid3.3300 x 800
Ask4.0500 x 800
Day's Range3.4300 - 3.5700
52 Week Range1.6800 - 15.0000
Volume45,639
Avg. Volume120,837
Market Cap237.293M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1340
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GRCL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gracell Biotechnologies Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
Advertisement
Advertisement